BELITE BIO, INC Logo

BELITE BIO, INC

Developing novel oral therapies for retinal degenerative eye diseases like GA and Stargardt disease.

BLTE | US

Overview

Corporate Details

ISIN(s):
US07782B1044
LEI:
Country:
United States of America
Address:
12750 HIGH BLUFF DRIVE SUITE 475, 92130 SAN DIEGO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Belite Bio, Inc. is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics for retinal degenerative eye diseases with significant unmet medical needs. The company's primary targets include atrophic age-related macular degeneration (specifically Geographic Atrophy, or GA) and Stargardt disease (STGD1). Its therapeutic pipeline is built on a proprietary portfolio targeting Retinol Binding Protein 4 (RBP4). The lead candidate, Tinlarebant (LBS-008), is a novel oral therapy designed to reduce the accumulation of ocular toxins that contribute to disease progression. Tinlarebant is in late-stage development with multiple Phase 3 trials and has received numerous regulatory designations, including Orphan Drug, Fast Track, Breakthrough Therapy, and Rare Pediatric Disease designations in the U.S. and other key markets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all BELITE BIO, INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BELITE BIO, INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BELITE BIO, INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Shuttle Pharmaceuticals Holdings, Inc. Logo
Develops drugs to enhance radiation therapy for cancer and offers predictive diagnostics.
United States of America SHPH
Siegfried Holding AG Logo
Global CDMO providing development and manufacturing of APIs and finished drugs for the pharma industry.
Switzerland SFZN
SIGA TECHNOLOGIES INC Logo
Develops antiviral drugs for global health security against biothreats and infectious diseases.
United States of America SIGA
Silexion Therapeutics Corp Logo
Developing a local drug delivery platform to treat KRAS-driven cancers and solid tumors.
United States of America SLXN
Develops oncolytic viruses and immunotherapeutics to destroy difficult-to-treat cancer cells.
South Korea 215600
Silo Pharma, Inc. Logo
Develops novel psychedelic & traditional therapies for pain and central nervous system disorders.
United States of America SILO
SINOVAC BIOTECH LTD Logo
Biopharmaceutical firm developing vaccines against infectious diseases like COVID-19 and Hepatitis.
United States of America SVA
Sionna Therapeutics, Inc. Logo
Developing novel NBD1 stabilizers and CFTR modulators to treat cystic fibrosis.
United States of America SION
SK biopharmaceuticals Co., Ltd. Logo
Develops and commercializes CNS and oncology therapies for global markets, focusing on the U.S.
South Korea 326030
SK Bioscience Co.,Ltd Logo
A global biotech firm developing vaccines for diseases like COVID-19, influenza, and shingles.
South Korea 302440

Talk to a Data Expert

Have a question? We'll get back to you promptly.